ClinicalTrials.gg
RecruitingNCT06011291Updated Oct 27, 2023

A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer

A Phase 1 interventional study of SYH2051 tablets and Intensity-Modulated Radiation Therapy (IMRT) in Solid Tumors and Head and Neck Cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-27.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 173 studies in Head and Neck Neoplasms with a site in China — 86 open to participants now, 95 under way, 12 of them phase 3. Head and Neck Neoplasms · China.

Planned enrollment
76th of 145
73 · median 85
Started
2023
with 12 others
Phase 1
24 of 173
14 open now
Primary completion
2024-12
later than 7 of 94 live
Registered
96th of 173
by date

Among the 173 studies in Head and Neck Neoplasms with a site in China, this one is the 76th largest by planned enrollment of the 145 interventional ones that give a count, is one of 13 that started in 2023, is one of 24 in phase 1, reaches primary completion later than 7 of the 94 other live ones, and was the 96th registered.

Head and Neck Neoplasms

2,716 studies on the registry are indexed under Head and Neck Neoplasms; 598 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

86 of the 173 studies in Head and Neck Neoplasms with a site in China are open now. Recruiting first, the newest first:

81 more — sign in →

All 86 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Head and Neck Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter, dose-escalation phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of SYH2051 in patients with advanced solid tumors or in combination with radiotherapy (RT) in patients with locally advanced head and neck cancer.

03

Conditions studied

  • Solid Tumors
  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old, male or female;
  2. Phase Ia: Patients with or cytologically confirmed advanced solid tumors, for whom there is no standard therapy available, or ineffective or intolerant to standard therapy. Phase Ib/Ic: Patients with histologically or cytologically confirmed locally advanced head and neck cancer suitable for radiotherapy alone;
  3. Eastern Collaborative Oncology Group () Performance Status of 0\~1;
  4. Patients in medical conditions to be able to receive radiotherapy (for phase Ib/Ic);
  5. of >3 months;
  6. At least one (excluding patients in phase Ic combined with radiotherapy);
  7. Patients with adequate hematologic, hepatic, renal and coagulation function;
  8. Patients are not pregnant or lactating and required ;
  9. Patients who are willing to provide written form (ICF) before the beginning of the study.

Exclusion criteria

Exclusion Criteria:

  1. Any antineoplastic therapy such as chemotherapy, biologic therapy, endocrine therapy, or immunotherapy within 4 weeks before the first dose of the study drug (or within 5 half-lives of other unmarketed study drugs, whichever is longer), except for the following:

    1. 6 weeks for Nitrosoureas or mitomycin C;
    2. 2 weeks or five half-lives (whichever is longer) for oral fluorouracil and small molecule targeted drugs;
    3. 2 weeks for Chinese herbal medicine with antineoplastic indications;
  2. Patients with previous (within 2 years before screening) or concurrent other (only for phase Ib/Ic);
  3. Patients had undergone major organ surgery (excluding needle ) within 4 weeks before the first dose, with obvious trauma, or require elective surgery during the study;
  4. Severe, non-healing fractures within 4 weeks before the first dose of the study drug;
  5. The adverse reactions of previous antineoplastic therapy have not recovered to ≤grade 1 as determined by (CTCAE) v5.0 criteria;
  6. Patients who had received treatment with any drug that is a medium or strong inhibitor or inducer of cytochrome P450 (CYP) 3A4/5 enzyme activity within 2 weeks before screening or need to continue receiving such drugs;
  7. Active and/or carcinomatous meningitis;
  8. Concurrent serious and/or uncontrolled medical conditions at screening (e.g., severe );
  9. Patients with abnormal thyroid function were not allowed, except those with euthyroid function after drug control;
  10. History of severe cardiovascular disease;
  11. History of myopathy or raised creatine kinase (CK) >5 times the (ULN);
  12. Known or intolerance to any component of the study drug or its ;
  13. History of disease, immunodeficiency disease, including testing positive or other acquired, congenital immunodeficiency diseases, or organ transplantation;
  14. Active virus, virus or active syphilis infection;
  15. Active dysphagia, malabsorption or other chronic gastrointestinal diseases or conditions that may hamper compliance and/or absorption of the study drug;
  16. Other ineligibilities according to the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
73 participants (estimated)

Study arms

  • Experimental
    Arm A: SYH2051 monotherapy dose escalation in advanced solid tumors (Phase Ia)

    Drug: SYH2051 tablets

  • Experimental
    Arm B: SYH2051+RT dose escalation in locally advanced head and neck cancer (Phase Ib)

    Drug: SYH2051 tablets · Radiation: Intensity-Modulated Radiation Therapy (IMRT)

  • Experimental
    Arm C: SYH2051+RT dose expansion in locally advanced head and neck cancer (Phase Ic)

    Drug: SYH2051 tablets · Radiation: Intensity-Modulated Radiation Therapy (IMRT)

Interventions

  • Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.

  • RadiationIntensity-Modulated Radiation Therapy (IMRT)

    Radical or adjuvant radiotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs)

    Time frame: 31 days for Arm A and 11 weeks for Arm B

  2. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: 2 years

  3. Maximum tolerated dose (MTD)(if any) or maximum administrated dose (MAD)

    Time frame: up to 1 year

  4. Recommended phase 2 dose (RP2D) of SYH2051 in combination with RT

    Time frame: 2 years

Secondary outcomes

  1. Phase Ia: Maximum Plasma Concentration (Cmax)

    Time frame: 1 years

  2. Phase Ia: Time to Maximum Plasma Concentration (Tmax)

    Time frame: 1 years

  3. Phase Ia: Area under the plasma concentration-time curve from time zero to time of last measurable concentration(AUC0-last)

    Time frame: 1 years

  4. Phase Ia: Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)

    Time frame: 1 years

  5. Objective response rate (ORR)

    Time frame: 2 years

  6. Disease Control Rate (DCR)

    Time frame: 2 years

  7. Duration of locoregional control (DoLC)

    Time frame: 2 years

  8. Phase Ib and Ic: Concentrations of SYH2051

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2024, 16 months after the start.

Of 86 industry-sponsored phase 1 interventional studies under Head and Neck Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 16 months is below that.

Counting every sponsor, half of 177 studies reached it within 45 months; a quarter within 31 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 25, 2023
StartActual
Aug 15, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Aug 31, 2025
Last update
Oct 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06011291
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Aug 15, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Oct 27, 2023

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ATM Inhibitor SYH2051

Start the discussion